BUY MBP CARFILZOMIB FOR INJECTION CARFILNAT 60MG VIAL BEST PRICE ONLINE IN NIGERIA LAGOS ABUJA KANO AND PORTHARCOURT AT MYBIGPHARMACY.COM

Description

Dear friend, this medication requires a prescription or medical license before it can be delivered to you. kindly ensure that you provide us with a reliable contact information at checkout, mybigpharmacy team will be in touch with you to obtain required document before your order is confirmed thank you for trusting mybig pharmacy with your health. Carfilzomib for injection is an anticancer medicine used mainly to treat multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is typically used in patients whose disease has returned or has not responded adequately to previous treatments. Carfilzomib belongs to a class of medicines known as proteasome inhibitors, which work by disrupting the normal process that cancer cells use to break down proteins, leading to cell death.

Carfilzomib works by selectively and irreversibly inhibiting the proteasome, a structure inside cells that breaks down damaged or unnecessary proteins. Cancer cells, especially myeloma cells, rely heavily on the proteasome to survive and multiply. When the proteasome is blocked by carfilzomib, abnormal proteins accumulate inside the cancer cell, causing stress and ultimately cell death. Normal cells are less affected because they are less dependent on this pathway.

Carfilzomib is given by intravenous injection and must be administered by trained healthcare professionals in a hospital or specialist oncology setting. It is usually given as an infusion over a specific period of time, depending on the treatment protocol. Carfilzomib is commonly used in combination with other medicines such as dexamethasone, lenalidomide, or daratumumab to improve treatment effectiveness. Treatment is given in cycles, with rest periods between cycles to allow the body to recover.

Before receiving carfilzomib, patients usually receive fluids to reduce the risk of kidney problems and help prevent complications. Premedication such as steroids may also be given to reduce the risk of infusion-related reactions. During treatment, patients are closely monitored for side effects, especially during the first few doses.

One of the most important side effects of carfilzomib is its potential effect on the heart. It can cause heart failure, shortness of breath, chest pain, irregular heartbeat, or high blood pressure. Patients with existing heart conditions require careful monitoring. Sudden weight gain, swelling of the legs, or difficulty breathing should be reported immediately.

Carfilzomib can also affect kidney function, especially in patients with pre-existing kidney disease or dehydration. Regular blood tests are done to monitor kidney function, electrolytes, and overall hydration status. Adequate fluid intake is essential unless otherwise advised by a healthcare professional.

Other common side effects include fatigue, anaemia, low platelet counts, shortness of breath, fever, nausea, diarrhoea, and muscle or joint pain. Because carfilzomib can suppress bone marrow function, patients may be more prone to infections, bruising, or bleeding. Any signs of infection such as fever, chills, or sore throat should be reported promptly.

Carfilzomib may also increase the risk of blood clots, including deep vein thrombosis or pulmonary embolism, especially when used in combination with certain other medicines. Patients may be given blood thinners or advised to watch for symptoms such as leg swelling, chest pain, or sudden shortness of breath.

Infusion-related reactions can occur, especially during early doses. Symptoms may include fever, chills, flushing, shortness of breath, or low blood pressure. These reactions are usually managed with supportive treatment and close monitoring.

Carfilzomib can cause harm to an unborn baby and should not be used during pregnancy. Effective contraception is required for both men and women during treatment and for a period after the last dose. Breastfeeding is not recommended while receiving this medicine.

Patients receiving carfilzomib require regular blood tests to monitor blood counts, kidney function, liver function, and electrolytes. Ongoing assessment helps ensure treatment remains safe and effective and allows early detection of side effects.

Although carfilzomib is a powerful medicine with potential risks, it has significantly improved treatment outcomes for many people with multiple myeloma. When used under specialist supervision with careful monitoring, it can help control disease progression, improve symptoms, and extend survival.